Log In
Print
BCIQ
Print
Print this Print this
 

MBX-700

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionNon-nucleoside HCV NS5B inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection
Regulatory Designation

Partner

Microbiotix Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today